Calypso Biotech
ExitedCalypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.
Calypso Biotech has raised €20M across 1 funding round from 2 investors, most recently a Series A round in Jan 2019. Based in Geneva, Netherlands; founded 2013; active in Healthtech. Acquired by Novartis in 2024. Data as of 28 Oct 2026.
Total raised
€20M
€20,000,000
Funding rounds
1
Investors
2
distinct backers
Active since
2019-01
latest 2019-01
Funding by year
EUR raised per yearCalypso Biotech — funding by year — interactive chart.
Data table
| Calypso Biotech — funding by year | |
|---|---|
| 2018 | €20M |
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series A | €20M | Gilde Healthcare,INKEF Capital | View deal → |
Exit
Type
acquisition
Date
Jan 2024
Value
€425M
Acquiror
Novartis (Switzerland)
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData